HI-GREAT Group Holding Company filed a Form 12b-25 notifying the SEC that its Quarterly Report for the period ended September 30, 2025 could not be filed on time because the issuer requires additional time for its auditors to complete the review. The company signed the notification on April 10, 2026.
Hi-Great Group Holding Company reported financial results for the period ended September 30, 2025, reflecting development-stage operations with modest revenue and ongoing losses. For the nine months, sales were $34,518 compared with $55,700 a year earlier, producing gross profit of $13,854. Operating expenses of $58,559 led to a net loss of $44,268, close to the prior-year loss of $43,006.
At September 30, 2025, cash totaled $7,986 and total assets were $72,286. Liabilities were $277,282, including $171,037 of accrued licensing royalties owed to a related party, resulting in stockholders’ deficit of $204,996 and an accumulated deficit of $937,062. Management notes a going concern uncertainty, stating the company has not yet generated revenues sufficient to cover operating costs and remains dependent on external financing.
The company remains a development-stage business involved in agritourism and selling SellaCare-branded herbal supplements under a worldwide related-party license, while pursuing an exclusive global licensing agreement related to the KRAS gene and planning expansion into cosmetics. Shares outstanding were 102,500,000 as of September 30, 2025, after equity grants to an officer and a service provider. Management concluded disclosure controls and procedures were not effective, though it reported no material changes in internal control during the quarter.
HI-GREAT GROUP HOLDING COMPANY filed a late-filing notice stating it will not submit its Form 10-Q for the period ended September 30, 2025 by the normal deadline. The company explains that its auditors need additional time to complete their review of the quarterly report and related financial disclosures.
The company indicates it intends to file the quarterly report as soon as practicable after the financial statements and disclosures review is completed, consistent with the extension framework provided under Rule 12b-25.